<DOC>
	<DOCNO>NCT00711906</DOCNO>
	<brief_summary>Malaria major contributor disease burden Sub-Saharan Africa , pregnant woman child vulnerable population . Malaria pregnancy increase risk abortion , prematurity , maternal anaemia , low birth weight ( LBW ) , perinatal , neonatal infant mortality . For prevention control malaria pregnancy , Intermittent Preventive Treatment ( IPT ) , insecticide treat net ( ITNs ) case management malaria anemia recommend . HIV infection pregnancy increase risk malaria , LBW , post-natal mortality also anaemia . In pregnant woman , HIV infection decrease efficacy IPT medicine sulfadoxine-pyrimethamine ( SP ) , treatment proven efficacy safety IPT recommend World Health Organization ( WHO ) . Unfortunately , document increase resistance SP , cotrimoxazole ( CTX ) could alternative : many study Zambia Uganda demonstrate reduces mortality morbidity HIV infect person , CTX prophylaxis significantly improve birth outcome immuno-suppressed HIV woman . Unfortunately , yet information effectiveness prevent placental malaria infection , maternal anaemia LBW . Thus study , aim establish safety efficacy daily CTX prevent malaria infection pregnancy consequence , HIV infect non-infected pregnant woman . This information urgently need assist issue guideline IPT pregnancy .</brief_summary>
	<brief_title>Daily Co-trimoxazole Prophylaxis Prevent Malaria Pregnancy</brief_title>
	<detailed_description>Malaria major contributor disease burden Sub-Saharan Africa , pregnant woman child vulnerable population . P. falciparum infection pregnancy lead parasite sequestration placental vascular space , increase risk abortion , stillbirth , prematurity , intrauterine growth retardation , maternal anaemia , low birth weight ( LBW ) , perinatal , neonatal infant mortality . In low transmission area , malaria evolve towards severe disease high risk mortality . In endemic area , still associate maternal anaemia , LBW stillbirth . For prevention control malaria pregnancy , WHO recommend Intermittent Preventive Treatment ( IPT ) , insecticide treat net ( ITNs ) case management malaria anemia . HIV pregnancy increase risk malaria , LBW , post-natal mortality also anaemia , suggest synergistic interaction HIV malaria . In pregnant woman , HIV-1 infection decrease efficacy sulfadoxine-pyrimethamine ( SP ) IPT , although 2 dos 2nd 3rd trimester still reduce peripheral parasitaemia , placental infection maternal anaemia . To date , SP treatment data efficacy safety IPT : WHO recommend least 2 dos first trimester . But documented increase SP resistance , cotrimoxazole ( CTX ) could alternative : many study Zambia Uganda demonstrate reduces mortality morbidity HIV infected individual , CTX prophylaxis significantly improve birth outcome woman CD4 count &lt; 200 . Concurrent administration SP CTX associate increase incidence severe adverse reaction HIV-infected patient . WHO promote CTX alternative SP IPT immuno-compromised HIV-infected pregnant woman . Unfortunately , information effectiveness daily CTX prevent placental malaria infection , maternal anaemia LBW . In past , CTX use treat malaria child daily use CTX non-pregnant HIV-infected adult associate 70 % reduction incidence clinical malaria . In study , target HIV infect non-infected pregnant woman CD4≥ 200/µL , aim establish safety efficacy daily CTX prevent malaria infection pregnancy consequence , assume CTX inferior SP reduce placental parasitaemia : information urgently need assist issue guideline IPT pregnant woman .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Confirmed pregnancy ( palpable fundus and/ positive pregnancy test ) Gestational age 16 28 week . Informed consent patient ( parent/ guardian patient le 18 year age ) No symptoms consistent malaria Willingness deliver health facility Willingness adhere requirement study ( include HIV1 test ) History allergy study drug , previous history allergy sulpha drug History presence major illness likely influence pregnancy outcome include diabetes mellitus , severe renal heart disease , active tuberculosis , prior randomization ; Any significant illness require hospitalization ; Intent move study catchment 's area delivery deliver relative 's home catchment 's area ; Prior enrolment study concurrent enrolment another study Severe anaemia ( Hb &lt; 7 g/dl ) Previous history unfavourable pregnancy outcome : preeclampsia , caesarean section , stillbirth . Being HIV infect already receive CTX prophylaxis ARV treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>HIV</keyword>
	<keyword>Intermittent Preventive Treatment</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>